Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Inhibits human amidolytic and kininogenase activities of tissue kallikrein. Additionally we are shipping serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 4 Kits (9) and serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 4 Proteins (5) and many more products for this protein.
Showing 10 out of 46 products:
Human Polyclonal SERPINA4 Primary Antibody for FACS, IHC (p) - ABIN391661
Chai, Chen, Chao, Chao: Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. in The Journal of biological chemistry 1993
Show all 3 references for ABIN391661
KBP reduces expression of VEGF (show VEGFA Antibodies) and HIF-1alpha (show HIF1A Antibodies) nuclear translocation
Increased kallistatin levels in type 1 diabetes and its relation with carotid intima media thickness may reflect vascular dysfunction and suggest a link between micro- and macro-angiopathy.
reveal novel mechanisms of kallistatin in inducing apoptosis and autophagy in breast cancer cells
crystal structure of kallistatin 1.9 A resolution
Kallistatin protects against renal ischemia-reperfusion injury by blocking oxidative stress and renal inflammation.
Kallistatin's heparin-binding site is crucial for preventing TGF-beta (show TGFB1 Antibodies)-induced miR (show MLXIP Antibodies)-21 and oxidative stress, while its active site is key for stimulating the expression of eNOS (show NOS3 Antibodies).
Plasma kallistatin is a novel marker for severe community-acquired pneumonia prognosis.
decreased SPTBN1 (show SPTBN1 Antibodies) and kallistatin gene expression associated with decreased relapse-free survival in hepatocellular carcinoma
these findings added the knowledge for us to understand the anti-angiogenic mechanism of kallistatin, which suggested that the rhKal could be worth as a candidate compound for further development for the purpose of anti-angiogenic therapies
A novel role of kallistatin in preventing breast tumor growth and mobility by direct interaction with LRP6 (show LRP6 Antibodies).
As a potent antioxidant and anti-inflammation agent, kallistatin may also hold therapeutic promise in cardiometabolic disorders.
Inhibits human amidolytic and kininogenase activities of tissue kallikrein. Inhibition is achieved by formation of an equimolar, heat- and SDS-stable complex between the inhibitor and the enzyme, and generation of a small C-terminal fragment of the inhibitor due to cleavage at the reactive site by tissue kallikrein.
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4
, serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4
, kallikrein inhibitor
, peptidase inhibitor 4
, protease inhibitor 4 (kallistatin)
, serpin A4